How big is the APAC Biguanide Market?

The APAC Biguanide Market size is expected to reach USD 1.97 billion in 2024 and grow at a CAGR of 2% to reach USD 2.17 billion by 2029. Read More

What is the current APAC Biguanide Market size?

In 2024, the APAC Biguanide Market size is expected to reach USD 1.97 billion. Read More

Who are the key players in APAC Biguanide Market?

Takeda, Bristol-Myers Squibb, Glenmark, Merck and Co. and Sanofi Aventis are the major companies operating in the APAC Biguanide Market. Read More

What years does this APAC Biguanide Market cover, and what was the market size in 2023?

In 2023, the APAC Biguanide Market size was estimated at USD 1.93 billion. The report covers the APAC Biguanide Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the APAC Biguanide Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

APAC Biguanide Market Share

Market Share of APAC Biguanide Industry

The Asia-Pacific biguanide market is fragmented, with manufacturers like Takeda, Merck, Sanofi, GlaxoSmithKline, Bristol-Myers Squibb, and Boehringer Ingelheim Pharmaceuticals having a global market presence and the market is highly competitive due to other generic drugs manufacturers' presence.

APAC Biguanide Market Leaders

Takeda
Bristol-Myers Squibb
Glenmark
Merck and Co.
Sanofi Aventis

*Disclaimer: Major Players sorted in no particular order